selective, reversible LSD1 inhibitor

<100 mg orally QW, in Ph. II for 1L ES-SCLC

from 300k+ cmpd HTS, SBDD + opt.

J. Med. Chem., Oct. 9, 2020

Celgene/Bristol Myers Squibb, San Diego, CA

CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks